Ischemic Stroke with Essential Thrombocythemia: A Case Series

被引:26
作者
Kato, Yuji [1 ]
Hayashi, Takeshi [1 ]
Sehara, Yoshihide [1 ]
Deguchi, Ichiro [1 ]
Fukuoka, Takuya [1 ]
Maruyama, Hajime [1 ]
Horiuchi, Yohsuke [1 ]
Nagamine, Yuito [1 ]
Sano, Hiroyasu [1 ]
Tanahashi, Norio [1 ]
机构
[1] Saitama Med Univ, Saitama Int Med Ctr, Dept Neurol & Cerebrovasc Med, Hidaka, Hidaka, Saitama 3501298, Japan
关键词
Ischemic stroke; essential thrombocythemia; JAK2 V617F mutation; antiplatelet therapy; cytoreductive therapy; POLYCYTHEMIA-VERA; MYELOPROLIFERATIVE NEOPLASMS; RISK-FACTORS; THROMBOSIS; CRITERIA;
D O I
10.1016/j.jstrokecerebrovasdis.2014.12.012
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: Essential thrombocythemia (ET) is considered a rare cause of stroke partly because it is not detected if the platelet count is not elevated. However, early detection of ET is important because thrombosis can recur frequently, unless adequately treated. Methods: We retrospectively collected data from 10 stroke cases with ET. Clinical characteristics, location of stroke, laboratory data (platelet and leukocyte count, hemoglobin, and JAK2 V617F mutation), and treatment were reviewed. Results: The population consisted of 7 women and 3 men aged 18-83 years. Most patients had atherosclerotic risk factors. Half of the patients had a history of ischemic stroke. In 8 patients, ischemic stroke was the first manifestation of ET. Of 13 acute cerebrovascular events, 4 were transient ischemic attacks and 9 were cerebral infarctions. Three patients presented with watershed-type infarcts without large artery stenosis. Two patients had atherosclerotic stenosis of the large artery and experienced atherothrombotic infarction. The mean platelet count was 966 +/- 383 x 10(9)/L. JAK2 V617F mutation was found in 5 of 7 patients. Despite treatment with combined antiplatelet and cytoreductive therapy in all patients, 3 experienced recurrent ischemic stroke. Conclusions: These findings suggest that ET is an adjunctive risk factor for stroke and the patients with ET are subject to watershed-type infarcts even in the absence of large artery stenosis. Early diagnosis of ET and strict management of vascular risk factors may help prevent additional cerebrovascular events. (C) 2015 by National Stroke Association
引用
收藏
页码:890 / 893
页数:4
相关论文
共 14 条
  • [1] ISCHEMIC STROKE AS FIRST MANIFESTATION OF ESSENTIAL THROMBOCYTHEMIA - REPORT OF 6 CASES
    ARBOIX, A
    BESSES, C
    ACIN, P
    MASSONS, JB
    FLORENSA, L
    OLIVERES, M
    SANSSABRAFEN, J
    [J]. STROKE, 1995, 26 (08) : 1463 - 1466
  • [2] Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: Relationship with thrombosis occurrence and JAK2 V617F allele burden
    Arellano-Rodrigo, Eduardo
    Alvarez-Larran, Alberto
    Reverter, Juan-Carlos
    Colorner, Dolors
    Villarnor, Neus
    Bellosillo, Beatriz
    Cervantes, Francisco
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2009, 84 (02) : 102 - 108
  • [3] Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status
    Carobbio, Alessandra
    Finazzi, Guido
    Guerini, Vittoria
    Spinelli, Orietta
    Delaini, Federica
    Marchioli, Roberto
    Borrelli, Giovanna
    Rambaldi, Alessandro
    Barbui, Tiziano
    [J]. BLOOD, 2007, 109 (06) : 2310 - 2313
  • [4] D'Ambrosio Daniele, 2008, Cases J, V1, P354, DOI 10.1186/1757-1626-1-354
  • [5] Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments
    De Stefano, Valerio
    Za, Tommaso
    Rossi, Elena
    Vannucchi, Alessandro M.
    Ruggeri, Marco
    Elli, Elena
    Mico, Caterina
    Tieghi, Alessia
    Cacciola, Rossella R.
    Santoro, Cristina
    Gerli, Giancarla
    Vianelli, Nicola
    Guglielmelli, Paola
    Pieri, Lisa
    Scognamiglio, Francesca
    Rodeghiero, Francesco
    Pogliani, Enrico M.
    Finazzi, Guido
    Gugliotta, Luigi
    Marchioli, Roberto
    Leone, Giuseppe
    Barbui, Tiziano
    [J]. HAEMATOLOGICA, 2008, 93 (03) : 372 - 380
  • [6] Thrombotic disease in the myeloproliferative neoplasms
    Falanga, Anna
    Marchetti, Marina
    [J]. HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2012, : 571 - 581
  • [7] Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: Pathogenetic mechanisms and prevention
    Landolfi, Raffaele
    Cipriani, Maria Celeste
    Novarese, Linda
    [J]. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2006, 19 (03) : 617 - 633
  • [8] Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study
    Palandri, Francesca
    Polverelli, Nicola
    Catani, Lucia
    Ottaviani, Emanuela
    Baccarani, Michele
    Vianelli, Nicola
    [J]. ANNALS OF HEMATOLOGY, 2011, 90 (08) : 933 - 938
  • [9] Stroke in essential thrombocythemia
    Posfai, Eva
    Marton, Imelda
    Szoke, Anita
    Borbenyi, Zita
    Vecsei, Laszlo
    Csomor, Angela
    Sas, Katalin
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2014, 336 (1-2) : 260 - 262
  • [10] Ischaemic stroke and essential thrombocythemia: a series of 14 cases
    Richard, Sebastien
    Perrin, Julien
    Baillot, Pierre Alexandre
    Lacour, Jean Christophe
    Ducrocq, Xavier
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2011, 18 (07) : 995 - 998